C16H15F2N5
Neat
315.33
1223404-88-3; (R)-5-(2-(2, 5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1, 5-a]pyrimidin-3-amine; MFCD30802505; 5-[(2R)-2-(2, 5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1, 5-a]pyrimidin-3-amine; (R)-5-[2-(2, 5-Difluorophenyl)-1-pyrrolidinyl]pyrazolo[1, 5-a]pyrimidin-3-amine; 5-[(2R)-2-(2, 5-Difluorophenyl)-1-pyrrolidinyl]pyrazolo[1, 5-a]pyrimidin-3-amine; C16H15F2N5; Larotrectinib Impurity 6; Larotrectinib Impurity 7; Larotrectinib dfp-pppa impurity; 54Q4FL3GH3; SCHEMBL2241164; SCHEMBL29735068; PNTNLXBVYHOZQI-CQSZACIVSA-N; AC3259; BS-45255; SY251734; DB-179458; CS-0068879; Pyrazolo[1, 5-a]pyrimidin-3-amine, 5-[(2R)-2-(2 and 5-difluorophenyl)-1-pyrrolidinyl]-
5-[(2R)-2-(2, 5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1 and 5-a]pyrimidin-3-amine
InChI=1S/C16H15F2N5/c17-10-3-4-12(18)11(8-10)14-2-1-6-22(14)15-5-7-23-16(21-15)13(19)9-20-23/h3-5,7-9,14H,1-2,6,19H2/t14-/m1/s1